Translating these findings into clinical utility with a lifestyle biomarker panel or molecular targeted therapies requires a validation study applying the same analysis to a different database (potentially with individual BMI details), investigating individual biomarker signatures and predictive power in a protein expression database, such as Olink and exploring drug links with PCa patients with ABCD, including the Glucagon‐Like Peptide‐1 (GLP‐1) receptor agonists group of drugs, using other bioinformatic tools. The gene discussed is GLP1R; the disease is posterior cortical atrophy.